Navigation Links
Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
Date:11/24/2008

ingual tablet, is a novel compound with a unique human receptor signature. Schering-Plough anticipates a filing for the approval of asenapine in Europe in 2009 for treatment of schizophrenia, and treatment of manic episodes associated with bipolar 1 disorder. Asenapine is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder. The company acquired asenapine in November 2007 through its acquisition of Organon BioSciences, which developed the product.

The Phase III study was a placebo-controlled, double-blind, clinical trial with a randomized withdrawal design that evaluated the efficacy and safety of sublingually administered asenapine (5 or 10 mg BID) compared to placebo in the prevention of relapse in patients with schizophrenia. A total of 700 patients entered the open-label treatment with asenapine for up to 26 weeks. Of these, a total of 386 patients met criteria for stabilization on asenapine and were randomized to treatment in the 26-week double-blind placebo-controlled phase of the trial.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking stateme
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
2. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
3. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
4. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
5. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
6. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
7. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
10. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
11. Schering-Plough Reports Top-Line Results of the IDEAL Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... DENVER, Dec. 14 Corgenix Medical ... developer and marketer of diagnostic test kits, ... Massachusetts-based life sciences company, announced today a ... Galectin-3 diagnostic products in enzyme-linked immunosorbent assay ... BG Medicine is seeking regulatory clearance in ...
(Date:12/14/2009)... 14 Southridge LLC ("Southridge"), an ... companies, is pleased to announce that its affiliated fund ... to $15 million in equity financing to Imaging Diagnostic ... years of financing the growth of Imaging Diagnostic Systems, ... produce new developments in the field of early breast ...
(Date:12/14/2009)... /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC ... received a complete response letter from the U.S. ... New Drug Application ("NDA") for Onrigin(TM) (laromustine) injection ... that the FDA cannot approve the Company,s NDA ... address remaining issues. ,, Alan Kessman, Chief Executive ...
Breaking Medicine Technology:Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM) 2Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc. 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3Oncolytics Biotech 28R 29 Inc Accelerates Warrant Expiry Date 14341 1Oncolytics Biotech 28R 29 Inc Accelerates Warrant Expiry Date 14341 2University Hospitals Case Medical Center earns prestigious national award for excellence 58801 1University Hospitals Case Medical Center earns prestigious national award for excellence 58801 2Fresh Blood Boosts Survival in Trauma Patients 58799 1Fresh Blood Boosts Survival in Trauma Patients 58799 2
... Jan. 8 Corthera Inc. today announced,the initiation ... trial of,Relaxin, a naturally occurring peptide hormone that ... acute care illnesses., The trial will investigate ... acute heart failure. Approximately 330 patients will be,recruited ...
... 7 Baxter International,Inc. (NYSE: BAX ) ... develop recombinant Factor IX proteins to treat hemophilia ... IX therapy for,treatment of acute bleeding episodes and ... therapy for prophylaxis of bleeding in,hemophilia B patients. ...
Other Medicine Technology:Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 3
(Date:12/14/2009)... be linked to scans performed in 2007 , , MONDAY, ... exposing patients to far more radiation than previously thought and ... a year, two new studies claim. , Based on the ... Archives of Internal Medicine , the study authors, joined by ... on clinicians to limit radiation exposure to patients. , "CT ...
(Date:12/14/2009)... poorly treated and highly stigmatized, according to psychiatrists ... M.D., Ph.D. So these Washington University physicians have ... In "Demystifying Psychiatry," Zorumski and Rubin, who have ... patients and helping patient families, say some of ... result from a lack of understanding psychiatry and ...
(Date:12/14/2009)... Association (NBA) and the United Nations Foundation’s Nothing But Nets tipped ... presented by HP--to send anti-malaria bed nets to refugees in 11 ... of Giving and runs through January 31, 2010. ... ... Today, the National Basketball Association (NBA) and the United Nations Foundation’s ...
(Date:12/14/2009)... Dec. 14 Josie Raper, a 29 year-old mother ... six months with the help of the Dr. Siegal,s COOKIE ... the Joy Fit Club segment on NBC,s Today Show. The ... Bauer, airs twice a month and salutes those who have ... 2007 and has kept it off for two years. ,, ...
(Date:12/14/2009)... Athens, Ga. A new study published by researchers ... Center in Tampa, Fla., has found that cancer patients ... patients with cancer alone, even after controlling for factors ... But the study, published in the early online edition ... also argues that a diagnosis of dementia shouldn,t discourage ...
Breaking Medicine News(10 mins):Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4Health News:Book demystifies psychiatry for the general public 2Health News:Book demystifies psychiatry for the general public 3Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 2Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 3Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 4Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 2Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 3Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 4Health News:Study finds significantly worse outcomes in cancer patients with cognitive impairment 2Health News:Study finds significantly worse outcomes in cancer patients with cognitive impairment 3
... about $247 billion a year, experts say , , FRIDAY, ... problems in young Americans cost the nation about $247 ... federal government to make preventing these disorders and promoting ... Problems such as depression, anxiety, conduct disorders and substance ...
... Smart Balance, Inc. (Nasdaq: SMBL ) announced ... Balance, Inc., will make a presentation at the Roth Capital ... at 2 p.m. EST on Tuesday, February 17, 2009.Smart Balance,s ... conference attendees will be able to ask questions, but listeners ...
... Twenty-seven leading organizations from the clinical research community ... The American National Standards Institute ... conformity assessment system, is working to facilitate the ... clinical research activities. The Institute seeks the active ...
... DYNT ) today announced results for its fiscal ... results showed significant improvement over the three and six months ... December 31, 2008, improved to $89,917, compared to a pre-tax ... fiscal year. Net income for the quarter ended December 31, ...
... ), today announced that its Chief Financial Officer, Buck Phillips, will present ... Ritz-Carlton Laguna Niguel on Wednesday, February 18, 2009., Forum: ... Date: Wednesday, February 18, 2009, Time: ... Ritz-Carlton Laguna Niguel, ...
... New techniques used to examine hormones in feces and ... results about hormones and evolution. The new techniques allow ... range of mammals. , San Francisco State Biology Professor ... that examine social stress and how they correlate to ...
Other Medicine News:Health News:Report Urges Broader Effort to Stem Emotional Disorders in Youth 2Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 2Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 3Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 4Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 2Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 3Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 4Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 2Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 3Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 4Health News:Findings raise new questions about evolution of hormones in mammals 2
The AXIOM Artis TC is ideal for applications above and beyond standard cardioangiography, and features:, Single plane C-Arm, ceiling-mounted, Full-size CCD camera, ...
... Hybrid Imaging in Cardiology ... unmatched imaging solutions in cardiology. ... quality coronary CT angiography imaging ... visibility. Symbia TruePoint SPECTCT ...
... enables you to scan every beating heart at ... dose possible. A scanner using two X-ray ... It provides one-stop diagnosis in acute care; even ... rate. Combined with the Cardiac Engine, a unique ...
... paperless environment, providers can code the charge while ... their PDA while away from office, both directly ... to use an Encounter Form/Superbill, data entry can ... Insurance and patient payments are posted by reflecting ...
Medicine Products: